Abilitat®, OPC 14597
Adis R&D Profile
- 7 Downloads
Aripiprazole [OPC 14597, Abilitat®] is a quinolinone derivative under development as a potential antipsychotic agent. In November 2001, Otsuka announced that an NDA has been submitted to the US FDA for aripiprazole. The compound is undergoing phase III clinical testing with Otsuka in Japan and the UK.
KeywordsSchizophrenia Haloperidol Aripiprazole Psychotic Disorder Extrapyramidal Symptom
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
- 1.Mallikaarjun S, Salazar DE, Bramer SL. The pharmacokinetics, tolerability, and safety of aripirazole following single and mutiple oral dose administration. International Journal of Neuropsychopharmacology. 3 (Suppl 1): 123–124, Jul 2000. USA. [English]Google Scholar
- 2.Toru M, Miura S, Kudo Y. Clinical experiences of OPC-14597, a dopamine autoreceptor agonist in schizophrenic patients. Neuropsychopharmacology. 10 (Suppl Part 1): 122, May 1994. Japan. [English]Google Scholar
- 4.Kane JM, Ingenito G, Ali M. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. International Journal of Neuropsychopharmacology. 3 (Suppl 1): 124 (plus poster), Jul 2000. USA. [English]Google Scholar
- 5.Inoue A, Miki S, Seto M, et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. European Journal of Pharmacology. 321: 105–111, 19 Feb 1997 Japan. [English]PubMedCrossRefGoogle Scholar
- 6.Uwahodo Y, Kikuchi T, Tottori K, et al. Pharmacological profile of OPC-14597, a novel anti-psychotic drug (2): weak extrapyramidal side effects. Japanese Journal of Pharmacology. 67 (Suppl I): 144, 1995. Japan. [English]Google Scholar
© Adis International Limited 2002